Clinical Trial Detail

NCT ID NCT03047993
Title Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

chronic myelomonocytic leukemia

myelodysplastic syndrome

Therapies

Azacitidine + Telaglenastat

Age Groups: adult senior

Additional content available in CKB BOOST